Abstract: The specification describes a zirconia support comprising ?95 wt % ZrO2, wherein: the support has a crush strength of 20 to 140 N; the support has a total pore volume of 0.10 to 0.40 mL/g when measured by N2 physisorption; the support has an acid site density of 15 to 30 ?LNH3/m2; and the support has a basic site density of 0.006 to 0.015 wt %/m2 as measured by the MBOH test. Also described is a method for producing a zirconia supporting starting from zirconia or zirconium hydroxide as raw materials.

Abstract: An oral insert includes a plurality of manifolds and a plurality of fluid nozzles. A manifold switch is coupled to the plurality of manifolds. The manifold switch is configured to select which of the plurality manifolds is to receive fluid from a fluid source.

Abstract: A superconducting magnet system includes a coil support structure having a body, a superconducting magnet having a plurality of coils disposed about the body, and a helium vessel encompassing the coil support structure and the superconducting magnet. The superconducting magnet system includes a cooling system that includes a network of tubes disposed within the helium vessel and configured to transport helium within, wherein the network of tubes is retroactively thermally coupled to the plurality of coils. The cooling system includes a liquid helium storage system located within the helium vessel and a helium recondenser located outside the helium vessel. The cooling system includes one or more tubes coupling the helium storage system to the helium recondenser, wherein where the one or more tubes pass through the helium vessel is retroactively vacuum sealed to make the helium vessel a sealed helium vessel.

Abstract: The present disclosure includes a smart pet bowl to monitor pet feeding behavior, which includes a pet bowl to carry pet food or water or carry a bowl insert to carry pet food or water. The smart pet bowl also can include a load sensor associated with the pet bowl that is sensitive to load changes of pet food or water carried within the pet bowl. The load sensor has a sensitivity of +/?50 grams or less and load data collectable therefrom is at a sample rate from 10 to 150 samples per second in sequential time increments from about 0.01 second to 5 seconds. The smart pet bowl may also include a data communicator to communicate the load data over a computer network, a processor, and a memory storing instructions that, when executed by the processor, communicates the load data over the computer network.

Abstract: The present disclosure relates to the monitoring feeding behavior(s) of a pet(s), under the control of at least one processor. An example method includes obtaining load data from a load sensor of a pet bowl while the pet is interacting with contents of the pet bowl. The load sensor can have a sensitivity of +/?50 grams or less and the load data is obtained can occur at a sample rate from 10 samples to 150 samples per second. The example method can also include sequentially grouping the load data in 0.01 second to 5 second time increments, wherein individual time increments include multiple samples, and identifying a feeding behavior occurring within one or more of the time increments based on the load data resulting from the pet interacting with the pet bowl or the contents of the pet bowl.

Abstract: Responsive to a magnitude of current associated with power from a vehicle being supplied to upfitter loads approaching a predefined threshold, a controller discontinues supply of power to vehicle loads according to a user defined priority order of the vehicle loads such that the vehicle loads of lowest priority among the priority order of the vehicle loads are sequentially shed to maintain the magnitude less than the predefined threshold.

Abstract: A combination microwave and refrigerator system is provided. The microwave oven is connected to a source of power and has at least one control circuit for controlling the operation of the microwave oven. A first power supply outlet is provided on the microwave oven. A refrigerator is connected to the source of power by connection to the first power supply outlet. The control circuit is configured to disable the cooling operation of the refrigerator, when the microwave oven demands cooking power, and enable the cooling operation of the refrigerator when the microwave oven is not drawing cooking power. A sensor is provided in the microwave oven, and is configured to cause cooking power to the microwave oven to be turned off upon the sensor sensing a level of smoke.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-8 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: Benzodiazepine derivatives of formula (Ib) wherein: R1 is H or halo; Y is selected from O, S, SO, SO2 and NR; one or two of V, W and X is or are N or CH and the other one or two is or are CH; R2 is a group selected from C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, halo, —OR, —NHR?, —SOmNR2, —SOmR, nitro, —CO2R, —CN, —CONR2, —NHCOR and —NR11R12; each R is independently H or C1-C6 alkyl; R11 and R12 are each independently H or C1-C6 alkyl; or R11 and R12 form, together with the N atom to which they are attached, either (a) a morpholine ring which is optionally bridged by a —CH2— group linking two ring carbon atoms that are positioned para to each other, or (b) a spiro group of the following formula (b): R? is C3-C6 cycloalkyl; m is 1 or 2; n is 0, 1 or 2; and each of R3 to R10 is independently selected from H, C1-C6 alkyl, halo, —OR, -NR2,—NHR?, —SOmNR2, —SOmR, nitro, —CO2R, —CN, —CONR2, —NHCOR, —NR13R 4 whereinR13 and R14 form, together with the N atom to which they are attached, a morpholine ring, and th

Abstract: A process for preparing a compound of formula (II): includes reacting a compound of formula (VIII): with a compound of formula (XIV):

Abstract: Benzodiazepine derivatives of formula (Ie) wherein one R1 and R2 is a benzodiazepinyl-containing group of formula (II) in which R8 is H or halo; the other of R1 and R2 is a group Z selected from H, C3-C6 cycloalkyl, halo, —NHR9, benzyl, phenyl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, wherein phenyl, heterocyclyl and heteroaryl are unsubstituted or substituted by one or two substituents selected from 4- to 10-membered heterocyclyl which is unsubstituted or substituted by OR, and from C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, halo, —OR, —(CH2)mOR, —NR2, —(CH2)mNR2, —NHR?, —SOmNR2, —SOmR, —SR, nitro, —CO2R, —CN, —CONR2, —NHCOR, —CH2NR10R11 and —NR10R11, in which each R is independently H or C1-C6 alkyl, R? is C3-C6 cycloalkyl and m is 1 or 2; R9 is selected from phenyl and 4- to 10-membered heteroaryl wherein phenyl and heteroaryl are unsubstituted or substituted by halo; R10 and R11 are each independently H or C1-C6 alkyl; or R10 and R11 form, together with the

Abstract: A process for preparing a compound of formula (II): includes reacting a compound of formula (VIII): with a compound of formula (XIV):

Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.

Abstract: Apparatus and method for personalising participation in an activity comprising a plurality of user nodes, each user node including a sensor array serving to generate data in relation to a user at the node and a data processing device for receiving the generated data from the sensor array as to the user, the apparatus further comprising a computer system in communication with the sensor array in each node. This ensures a fluent and immediate personalised experience across the different user nodes.

Abstract: There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.

Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.